MENU
+Compare
IHE
ETF ticker: NYSE ARCA
AS OF
Jan 17 closing price
Price
$66.15
Change
-$0.95 (-1.42%)
Net Assets
614.34M

IHE stock forecast, quote, news & analysis

Category: @Health
IHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for IHE with price predictions
Jan 08, 2025

IHE's RSI Oscillator ascends from oversold territory

The RSI Indicator for IHE moved out of oversold territory on December 20, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for IHE just turned positive on January 07, 2025. Looking at past instances where IHE's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IHE advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IHE as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares US Pharmaceuticals ETF ETF is 55.93B. The market cap for tickers in the group ranges from 132.3M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is SAVA at 132.3M.

High and low price notable news

The average weekly price growth across all stocks in the iShares US Pharmaceuticals ETF ETF was 0%. For the same ETF, the average monthly price growth was 1%, and the average quarterly price growth was -2%. ITCI experienced the highest price growth at 33%, while TARS experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the iShares US Pharmaceuticals ETF ETF was 7%. For the same stocks of the ETF, the average monthly volume growth was -1% and the average quarterly volume growth was 56%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 75
Price Growth Rating: 55
SMR Rating: 73
Profit Risk Rating: 72
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
IHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com